急性早幼粒细胞白血病长期生存者的健康相关生活质量、症状负担与合并症
本研究邀请307例接受标准化疗的急性早幼粒细胞白血病(APL)长期生存者参与,评估其健康相关生活质量(HRQOL)、症状负担与合并症谱,并与年龄性别匹配的普通人群对照比较。中位随访14.3年,APL生存者在SF-36角色生理量表得分较普通人群差(-9.5;95%CI -15.7至-3.2,P=0.003),29%报告中度至重度疲乏,84.4%报告至少一种合并症,合并症患病率高于普通人群,且HRQOL随合并症数量呈明显差异。
要点
- APL长期生存者SF-36角色生理得分较普通人群差(-9.5;95%CI -15.7至-3.2,P=0.003)。
- 29%的APL长期生存者报告中度至重度疲乏。
- 84.4%的APL长期生存者报告至少一种合并症,患病率高于普通人群。
核心结论
- 接受标准化疗的APL长期生存者在治疗结束多年后仍未完全恢复,报告HRQOL受限和相当程度的症状负担。
研究设计与样本
- 本研究邀请307例接受标准化疗的APL长期生存者参与,评估HRQOL(SF-36)、症状负担(MDASI问卷)和合并症谱,并与年龄性别匹配的普通人群对照比较。
- 自诊断起中位随访时间为14.3年(四分位距11.1-16.9年)。
主要发现
- APL生存者SF-36角色生理量表得分较普通人群对照差(-9.5;95%CI -15.7至-3.2,P=0.003),差异有统计学和临床意义。
- 29%的患者报告中度至重度疲乏。
- 84.4%的患者报告至少一种合并症,APL生存者合并症患病率高于普通人群报告的患病率。
- HRQOL谱随合并症数量呈现明显差异。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The objective of this study was to investigate health-related quality of life (HRQOL), symptom burden, and comorbidity profile in long-term acute promyelocytic leukemia (APL) survivors treated with standard chemotherapy. Overall, 307 long-term APL survivors were invited to participate. HRQOL was assessed with the Medical Outcomes Study 36-Item Short-Form Health Survey (SF-36) and compared with that of age and sex-matched controls from the general population. Symptom burden was assessed with the MD Anderson Symptom Inventory (MDASI) questionnaire and comorbidity profile was also investigated. Median follow-up time since diagnosis was 14.3 years (interquartile range: 11.1-16.9 years). APL survivors had a statistically and clinically meaningful worse score for the role physical scale of the SF-36 (-9.5; 95% CI, -15.7 to -3.2, P = 0.003) than their peers in the general population. Fatigue was reported as moderate to severe by 29% of patients and 84.4% reported at least one comorbidity. Prevalence of comorbidity in APL survivors was higher than that reported by the general population. Also, marked variations were found in the HRQOL profile by number of comorbidities. Even many years after treatment ends, APL survivors treated with standard chemotherapy do not fully recover as they report HRQOL limitations and a substantial burden of symptoms.
引用
- Efficace F, Breccia M, Avvisati G, et al. Health-related quality of life, symptom burden, and comorbidity in long-term survivors of acute promyelocytic leukemia. Leukemia. 2018. PMID: 30573776. doi:10.1038/s41375-018-0325-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。